Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Timothy Swartz

Rheumatology Kalamazoo, MI Medical Doctor

NPI 1851393797 CMS profile 38333

555 W Crosstown Pkwy, Suite 201, Kalamazoo, MI 49008

Open in the dashboard

General payments

$5,620

399 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,083 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Timothy Swartz of Kalamazoo, MI is reported in the CMS Open Payments database as having received $5,620 across 399 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,083 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $44 1
2022 General $258 15
2021 General $1,995 129
2020 General $1,749 117
2019 General $1,574 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Swartz
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Timothy Swartz were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Timothy Swartz Rheumatology median Middle half National median
2019 $1,574 $744 $153–$2,687 $163
2020 $1,749 $462 $98–$2,027 $114
2021 $1,995 $531 $101–$2,153 $132
2022 $258 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $44 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $893 59 payments
  2. Janssen Biotech, Inc. $735 64 payments
  3. Amgen Inc. $682 52 payments
  4. Pfizer Inc. $493 39 payments
  5. Novartis Pharmaceuticals Corporation $464 32 payments
  6. E.R. Squibb & Sons, L.L.C. $401 29 payments
  7. UCB, Inc. $301 19 payments
  8. Celgene Corporation $207 15 payments
  9. Eisai Inc. $175 8 payments
  10. Collegium Pharmaceutical, Inc. $163 10 payments
  11. Other $1,105 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,606 398 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2024
  1. SIMPONI ARIA $500 47 payments
  2. COSENTYX $464 32 payments
  3. ORENCIA $401 29 payments
  4. HUMIRA $393 29 payments
  5. XELJANZ $370 26 payments
  6. RINVOQ $325 18 payments
  7. Cimzia $301 19 payments
  8. TREMFYA $235 17 payments
  9. STELARA $220 22 payments
  10. REMICADE $220 22 payments
  11. Other $3,263 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record